Molindone

CHEMBL460 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

276.4 g/mol

LogP

1.7

Phase

4

An antipsychotic medication used to treat schizophrenia, working by blocking dopamine receptors in the brain.

Masse moléculaire

276,3700 g/mol

LogP

1,70

TPSA

45,30 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pain Management Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Kidney Disease Stroke Hypertension Chronic Pain Heart Failure

Mécanisme d'action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2

InChI

InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3

Molecular Formula

C16H24N2O2

HBD / HBA

1 / 3

Liaisons Rotatives

3

Atomes Lourds

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An antipsychotic medication used to treat schizophrenia, working by blocking dopamine receptors in the brain.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Molindone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL460. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23897. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Molindone sur PillFYI

Structure

Données Clés

Formule: C16H24N2O2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.